

**NEKTAR**  
Nektar Therapeutics  
455 Mission Bay Boulevard South  
San Francisco, California 94158-2117

November 15, 2017

**VIA EDGAR**

Office of Healthcare and Insurance  
United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Ibolya Ignat, Senior Staff Accountant

**Re: Nektar Therapeutics  
Form 10-K for the Fiscal Year Ended December 31, 2016  
Filed March 1, 2017  
File No. 000-24006**

Dear Ms. Ignat:

We are in receipt of the letter from the staff (the “**Staff**”) of the Securities and Exchange Commission (the “**Commission**”) dated November 1, 2017, regarding the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation (the “**Company**”), on March 1, 2017. We hereby respectfully request that the Commission grant an extension of the deadline for the Company to provide its response to the Staff’s comment in the letter to November 24, 2017.

If you have any questions regarding this request, please do not hesitate to contact the undersigned at (415) 482-5570.

Sincerely,

/s/ Gil M. Labrucherie

---

Gil M. Labrucherie

Senior Vice President and Chief Financial Officer

cc: Angela Connell, Accounting Branch Chief, Division of Corporation Finance  
Jillian B. Thomsen, Senior Vice President, Finance and Chief Accounting Officer of Nektar Therapeutics  
Mark A. Wilson, Vice President and General Counsel of Nektar Therapeutics  
Sam Zucker, Esq., Sidley Austin LLP